Soleus Capital Master Fund, L.P. 13D and 13G filings for Rigel Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-02 09:56 am Purchase |
2023-12-31 | 13G | Rigel Pharmaceuticals, Inc. RIGL |
Soleus Capital Master Fund, L.P. | 944,258 5.400% |
21,956 (+2.38%) |
Filing |
| 2023-02-22 4:03 pm Purchase |
2023-02-21 | 13G | Rigel Pharmaceuticals, Inc. RIGL |
Soleus Capital Master Fund, L.P. | 922,302 5.300% |
922,302 (New Position) |
Filing |